Posts

Dermavant acquisition expands Organon’s dermatology por...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roi...

Bavarian eyes Mpox vaccine label expansion to include t...

The registrational trial is expected to support the approval for Bavarian’s mpox...

US Border Protection warns pharma of risks with incorre...

At the Outsourcing in Clinical Trials Conference, US government personnel advise...

EC approves AstraZeneca’s Fasenra for EGPA treatment

The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with r...

South Korean pricing reform suggests more flexible drug...

South Korea’s Ministry of Health and Welfare recently disclosed its proposal to ...

Merck-Gilead’s Combined HIV Treatment Sunlenca Shows Po...

A mid-phase trial featuring Gilead Sciences and Merck & Co.’s once-weekly HIV co...

Arcus’ HIF-2a Inhibitor Shows Positive Response Rate in...

The latest research on Arcus Biosciences’ experimental HIF-2a inhibitor suggests...

Marinus to cut workforce and explore options after Ztal...

Marinus Pharmaceuticals, a pharmaceutical company, has been dealt a blow after i...

GSK Responds to Pfizer’s RSV Approval with Data Aiming ...

Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit...

Takeda and BMC partner to decarbonise US healthcare sector

Takeda and the Boston Medical Center (BMC) have announced a partnership aimed at...

AbbVie and Richter partner for neuropsychiatric treatments

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new ...

US CDC AdCom recommends lowering the age for pneumococc...

The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’...

Pharma companies must adapt to keep pace with AI develo...

At the Outsourcing in Clinical Trials Conference, key opinion leaders shared pre...

AF stroke patients could benefit from earlier anticoagu...

New research casts doubt on current advice recommending AF patients wait up to 1...

LEO’s Adbry demonstrates long-term efficacy in atopic d...

The Phase III ECZTEND study reported that patients treated with Adbry demonstrat...

GSK pumps up to $800m for US manufacturing site upgrade

A new vaccines drug substance facility and R&D pilot plant, completed by the end...